Deep Apple
Services: Company Launch, Partnership Announcement, Messaging, Media Relations
Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.
Company Launch
Former execs from Pfizer obesity drug program have started a new biotech with $52M from VC fund ATP
Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries
By combining ensemble cryo-EM, deep learning, and molecular docking screens, the Apple Tree Partners backed start-up is identifying hits that promote signaling in GPCRs and other target classes
